Limits...
FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth.

Ding L, Niu C, Zheng Y, Xiong Z, Liu Y, Lin J, Sun H, Huang K, Yang W, Li X, Ye Q - J. Cell. Mol. Med. (2011)

Bottom Line: Here, we show that FHL1 physically and functionally interacted with oestrogen receptors (ERs), which are involved in breast cancer development and progression.Further analysis of 46 breast cancer samples showed that FHL1 expression negatively associated with oestrogen-responsive gene expression in breast cancer cells.These results suggest that FHL1 may play an important role in ER signalling as well as breast cancer cell growth regulation.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Oncology, Beijing Institute of Biotechnology, Beijing, China.

Show MeSH

Related in: MedlinePlus

FHL1 inhibits breast cancer cell growth. (A and B) ZR75–1 cells transfected with expression vector of FHL1 (A) or FHL1 siRNAs (B) were treated with or without 1 nM E2 and harvested at the indicated times. Cell number was determined by crystal violet assay. Values shown are mean ± S.D. of triplicate measurements and have been repeated three times with similar results. #P < 0.05 versus empty vector or control siRNA without E2. *P < 0.05 versus empty vector or control siRNA with E2. (C) ZR75–1 cells transfected with expression vector for FHL1 were treated with 100 nM 4-OHT or 100 nM ICI 182,780 in regular medium at the indicated times. Cell number was measured by crystal violet assay. *P < 0.05 versus empty vector without 4-OHT or ICI 182,780. #P < 0.05 versus empty vector with 4-OHT. $P < 0.05 versus empty vector with ICI 182,780. (D) ZR75–1 cells transfected with FHL1 siRNAs or control siRNA were plated in soft agar and assayed for colony number after 5 weeks. Representative images show colonies in soft agar (upper panel). Scale bar: 100 μm. Values shown are mean ± S.D. of triplicate measurements (lower panel) and have been repeated three times with similar results. *P < 0.01 versus control siRNA without E2. #P < 0.01 versus control siRNA with E2.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822495&req=5

fig06: FHL1 inhibits breast cancer cell growth. (A and B) ZR75–1 cells transfected with expression vector of FHL1 (A) or FHL1 siRNAs (B) were treated with or without 1 nM E2 and harvested at the indicated times. Cell number was determined by crystal violet assay. Values shown are mean ± S.D. of triplicate measurements and have been repeated three times with similar results. #P < 0.05 versus empty vector or control siRNA without E2. *P < 0.05 versus empty vector or control siRNA with E2. (C) ZR75–1 cells transfected with expression vector for FHL1 were treated with 100 nM 4-OHT or 100 nM ICI 182,780 in regular medium at the indicated times. Cell number was measured by crystal violet assay. *P < 0.05 versus empty vector without 4-OHT or ICI 182,780. #P < 0.05 versus empty vector with 4-OHT. $P < 0.05 versus empty vector with ICI 182,780. (D) ZR75–1 cells transfected with FHL1 siRNAs or control siRNA were plated in soft agar and assayed for colony number after 5 weeks. Representative images show colonies in soft agar (upper panel). Scale bar: 100 μm. Values shown are mean ± S.D. of triplicate measurements (lower panel) and have been repeated three times with similar results. *P < 0.01 versus control siRNA without E2. #P < 0.01 versus control siRNA with E2.

Mentions: To test the effect of FHL1 on breast cancer cell growth, the anchorage-dependent growth rate of ZR75–1 cells transfected with FHL1 or empty vector, or with FHL1 siRNAs or control siRNA, was examined. In the presence or absence of E2, ZR75–1 cells transfected with FHL1 grew more slowly than those with empty vector (Fig. 6A), whereas ZR75–1 cells transfected with FHL1 siRNAs grew faster than those with control siRNA (Fig. 6B). Similar results were observed in MCF7 cells (data not shown). In addition, in agreement with the results of the transcriptional experiments, the anti-oestrogens 4-OHT and ICI 182,780 further promoted the effect of FHL1 on breast cancer cell growth (Fig. 6C).


FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth.

Ding L, Niu C, Zheng Y, Xiong Z, Liu Y, Lin J, Sun H, Huang K, Yang W, Li X, Ye Q - J. Cell. Mol. Med. (2011)

FHL1 inhibits breast cancer cell growth. (A and B) ZR75–1 cells transfected with expression vector of FHL1 (A) or FHL1 siRNAs (B) were treated with or without 1 nM E2 and harvested at the indicated times. Cell number was determined by crystal violet assay. Values shown are mean ± S.D. of triplicate measurements and have been repeated three times with similar results. #P < 0.05 versus empty vector or control siRNA without E2. *P < 0.05 versus empty vector or control siRNA with E2. (C) ZR75–1 cells transfected with expression vector for FHL1 were treated with 100 nM 4-OHT or 100 nM ICI 182,780 in regular medium at the indicated times. Cell number was measured by crystal violet assay. *P < 0.05 versus empty vector without 4-OHT or ICI 182,780. #P < 0.05 versus empty vector with 4-OHT. $P < 0.05 versus empty vector with ICI 182,780. (D) ZR75–1 cells transfected with FHL1 siRNAs or control siRNA were plated in soft agar and assayed for colony number after 5 weeks. Representative images show colonies in soft agar (upper panel). Scale bar: 100 μm. Values shown are mean ± S.D. of triplicate measurements (lower panel) and have been repeated three times with similar results. *P < 0.01 versus control siRNA without E2. #P < 0.01 versus control siRNA with E2.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822495&req=5

fig06: FHL1 inhibits breast cancer cell growth. (A and B) ZR75–1 cells transfected with expression vector of FHL1 (A) or FHL1 siRNAs (B) were treated with or without 1 nM E2 and harvested at the indicated times. Cell number was determined by crystal violet assay. Values shown are mean ± S.D. of triplicate measurements and have been repeated three times with similar results. #P < 0.05 versus empty vector or control siRNA without E2. *P < 0.05 versus empty vector or control siRNA with E2. (C) ZR75–1 cells transfected with expression vector for FHL1 were treated with 100 nM 4-OHT or 100 nM ICI 182,780 in regular medium at the indicated times. Cell number was measured by crystal violet assay. *P < 0.05 versus empty vector without 4-OHT or ICI 182,780. #P < 0.05 versus empty vector with 4-OHT. $P < 0.05 versus empty vector with ICI 182,780. (D) ZR75–1 cells transfected with FHL1 siRNAs or control siRNA were plated in soft agar and assayed for colony number after 5 weeks. Representative images show colonies in soft agar (upper panel). Scale bar: 100 μm. Values shown are mean ± S.D. of triplicate measurements (lower panel) and have been repeated three times with similar results. *P < 0.01 versus control siRNA without E2. #P < 0.01 versus control siRNA with E2.
Mentions: To test the effect of FHL1 on breast cancer cell growth, the anchorage-dependent growth rate of ZR75–1 cells transfected with FHL1 or empty vector, or with FHL1 siRNAs or control siRNA, was examined. In the presence or absence of E2, ZR75–1 cells transfected with FHL1 grew more slowly than those with empty vector (Fig. 6A), whereas ZR75–1 cells transfected with FHL1 siRNAs grew faster than those with control siRNA (Fig. 6B). Similar results were observed in MCF7 cells (data not shown). In addition, in agreement with the results of the transcriptional experiments, the anti-oestrogens 4-OHT and ICI 182,780 further promoted the effect of FHL1 on breast cancer cell growth (Fig. 6C).

Bottom Line: Here, we show that FHL1 physically and functionally interacted with oestrogen receptors (ERs), which are involved in breast cancer development and progression.Further analysis of 46 breast cancer samples showed that FHL1 expression negatively associated with oestrogen-responsive gene expression in breast cancer cells.These results suggest that FHL1 may play an important role in ER signalling as well as breast cancer cell growth regulation.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Oncology, Beijing Institute of Biotechnology, Beijing, China.

Show MeSH
Related in: MedlinePlus